Abstract: A diagnostic test, and a device for conducting the test, for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction as a cause of patient chest pain is described. The diagnostic test comprises simultaneously detecting at least three selected cardiac markers with the use of at least three different monoclonal or polyclonal antibody pairs, each member of which is complementary to a different marker, which is released by heart muscle at varying stages after the onset of chest pain and is indicative of the cause of the chest pain.

Abstract: A cellulose binding domain (CBD) having a high affinity for crystalline cellulose and chitin is disclosed, along with methods for the molecular cloning and recombinant production thereof. Fusion products comprising the CBD and a second protein are likewise described. A wide range of applications are contemplated for both the CBD and the fusion products, including drug delivery, affinity separations, and diagnostic techniques.

Abstract: Method of assay of enzymatic activity, comprising projecting excitation light to a sample containing an enzyme, a substrate which forms a product by action of the enzyme, and a reference substance which is insensitive to the action of the enzyme but emits fluorescence; obtaining a first measured value of fluorescence intensity of the sample at a first wavelength region which includes fluorescence emitted by the substrate or the product at least, obtaining a second measured value of fluorescence intensity at a second wavelength region which is different from the first wavelength region for the first measured value and includes fluorescence emitted by the reference substance; and assaying the enzymatic activity from the ratio of the first measured value to the second measured value and apparatus for performing the method. The method assures high accuracy and high sensitivity of measurement in enzyme labeled immunoassay and enzyme labeled DNA hybridization.

Abstract: Methods and test kits are described which provide a reliable, sensitive and selective assessment of periodontal disease activity, peri-implantitis or HIV(+)-infection/AIDS-disease related periodontal diseases. The preferred methods and test kits are constructed to be easy and rapid chair-side tests. The method is based on the preparation and use of monoclonal antibodies which recognize the active mammalian matrix metalloproteinase-S (MMP-8) and is capable of differentiating between said active matrix metalloproteinase-8 and its inactive proform.

Abstract: The present invention relates to methods for diagnosis of susceptibility to alcoholism or the pathological effects of alcoholism based on detection of a genetic marker in an individual. The present invention is directed generally to methods and associated compositions and kits for detecting the presence of arylsulfatase A (ASA) pseudodeficiency (PD) mutations in humans. Detection of these mutations has been surprisingly found to be a strong indicator for susceptibility to alcoholism and/or susceptibility to alcohol's pathological effects, as well as an important marker in evaluating the likelihood of metachromatic leukodystrophy (MLD).

Abstract: Disclosed is a process for chemical finishing of fabrics, fibers or yarns wherein insoluble cellulosic polymers are reacted with carboxylic acids or esters thereof in the presence of a lipase. The cellulosic polymer may be cotton, viscose, rayon, lyocell, flax, linen, ramie, and all blends thereof; and blends thereof with polyesters, wool, polyamides, acrylics and polyacrylics. The lipase may be a microbial lipase, including a lipase obtained from yeast, e.g. Candida lipase, a bacterial lipase, e.g. Pseudomonas lipase, or a fungal lipase, e.g. Humicola or Rhizomucor lipases. Chemically modified lipases obtained by coupling polyethylene glycol to amino acid residues of the lipase may also be used.

Abstract: An allergen immunoassay method features the use of a combination of a) closely controlled 1) elevated temperatures for assay reactions, 2) low temperatures for reagents and samples, 3) times for assay steps and especially assay reaction times, 4) reagent concentrations, and 5) reagent amounts; b) the use of a fast and accurate method of sample preparation that removes dust and contaminants; c) the stabilization of samples to avoid auto- and antibody degradation and unwanted effects of sample contaminants; and d) the formation of a colored product to determine the amount of a specific allergen. This combination provides an assay that can be completed in a few hours while retaining the precision, accuracy, sensitivity and response curve of previous methods requiring much longer periods of time.

Abstract: The present invention is based on the discovery that a critical step in the cellular response to several cytokines is the activation (i.e. tyrosine phosphorylation) of a member of the Jak kinase family. In particular, several cytokines whose activity is mediated by the activation of Jak2 kinase are identified. The present invention provides novel methods for regulating the cellular response to these cytokines by inhibiting or enhancing the Jak kinase activity which mediates the response. Assays for identifying inhibitors of Jak kinase activity or cytokine-induced Jak kinase activation useful in the methods of the invention are also provided. Antibodies raised against peptide fragments of Jak1, Jak2, and Tyk2 kinase capable of specifically binding to these Jak kinases without interfering with kinase activity are also provided. In addition, the complete DNA coding sequence and amino acid structure of Jak2 kinase is provided by the invention.

Abstract: The present invention provides improved methods for the formation of glycosidic linkages. These methods are useful for the preparation of compounds of formula:NeuAc.alpha.(2.fwdarw.3)Gal.beta.(1.fwdarw.4)(Fuc.alpha. 1.fwdarw.3)GlcN(R').beta.(1.fwdarw.3)Gal.beta.

Abstract: New nuclear kinases that are regulated by signal transduction and that participate in phosphorylation cascades which regulate transcription and related methods for regulating transcription. The novel nuclear kinases play a vital role in gene expression, particularly with regard to leukemia in humans. The kinase is (i) substantially exclusively intranuclearly localized; (ii) capable of autophosphorylation; (iii) selectively bindable with antibodies raised against the RING3 portion of GST-RING3; (iv) of a molecular weight of from about 82.5 to about 92.7 kilodaltons; and (v) includes peptide sequences Asp-Ser-Asn Pro-Asp-Glu-Ile-Glu-Ile-Asp-Phe-Glu-Thr-Leu-Lys-Pro-Thr-Thr-Leu (SEQ ID NO: 1) and Ala-Val-His-Glu-Gln-Leu-Ala-Ala-Leu-Ser-Gln-Ala-Pro (SEQ ID NO: 2).

Abstract: The present invention is a method for assaying enzyme activity in a red blood sample. The method comprises these steps: (a) placing the following in a sample well: (1) a red blood sample containing an enzyme, (2) a substrate or substrates for the enzyme, (3) water, and (4) a buffer; (b) incubating the contents of the sample well for sufficient time and at sufficient temperature to allow for the formation of a fluorescent enzyme product should the enzyme be present in said red blood sample; (c) precipitating the hemoglobin; and (d) measuring the fluorescence of any fluorescent enzyme product formed in the sample well, directly from that sample well. The method of the invention may be used for assaying the activity of an enzyme, such as galactose-1-phosphate uridyl transferase (GALT) or biotinidase, in a red blood sample.

Abstract: This invention relates to polymers labeled with fluorescent dye to the point that significant fluorescence quenching occurs, such that degradation of the polymer results in fluorescence enhancement. The resulting fluorescence enhancement is useful for measuring the degradation of such polymers, for example as a result of enzymatic hydrolyis of a protein, carbohydrate, nucleic acid, or other natural or synthetic polymer.

Abstract: Mutant glycosidase enzymes are formed in which the normal nucleophilic amino acid within the active site has been changed to a non-nucleophilic amino acid. These enzymes cannot hydrolyze disaccharide products, but can still form them. Using this enzyme, oligosaccharides are synthesized by preparing a mixture of an .alpha.-glycosyl fluoride and a glycoside acceptor molecule; enzymatically coupling the .alpha.-glycosyl fluoride to the glycoside acceptor molecule to form a glycosyl glycoside product using the mutant glycosidase enzyme; and recovering the glycosyl glycoside product. Particular enzymes include a mutant form of Agrobacterium .beta.-Glucosidase in which the normal glutamic acid residue at position 358 is replaced with an alanine residue.

Abstract: One shortcoming of methotrexate chemotherapy is that previously responsive tumors can become refractory to methotrexate after continued exposure. Such methotrexate resistance may be due to underexpression of reduced folate carrier (RFC) protein. The present invention provides DNA molecules encoding human RFC. The present invention also relates to expression vectors comprising RFC-encoding DNA molecules, and to the use of such vectors to restore methotrexate sensitivity in mammalian cells. The present invention further relates to antibodies that bind with human RFC protein, and to methods of detecting human RFC protein using such antibodies.

Abstract: Methods for determining the concentration of an analyte in a sample in which an analyte gradient is established and brought into contact with one or more zones that contain binding members that interact with the analyte and thereby produce a detectable signal. Devices that may be used to practice the disclosed methods are also provided.

Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

Abstract: Disclosed is a novel .alpha.-glycosyl derivative of a catecholamine or its salt, said .alpha.-glycosyl derivative being prepared by allowing a saccharide-transferring enzyme together with or without glucoamylase to act on a solution containing an .alpha.-glucosyl saccharide and one of catecholamines in order to form an .alpha.-glycosyl derivative of said catecholamines, and recovering the resultant .alpha.-glycosyl derivative. The .alpha.-glycosyl derivative overcomes conventional drawbacks of catecholamines, and does not substantially exhibit or have a reducing activity and undesirable toxicity, but has a relatively-high stability and exerts the inherent physiological activities of catecholamines in vivo. Thus, the .alpha.-glycosyl derivative is advantageously used as a variety of pharmaceuticals in the form of an injection, tablet, etc.

Abstract: This invention relates to a diagnostic tests and devices for conducting such tests at the point of care or in a diagnostic laboratory for accurate, simple, and rapid assessment of chest pain. In particular, the invention relates to differential diagnosis of the origin of chest pain, e.g., whether the pain is cardiac in origin, and for differentiating between unstable angina ("UA"), myocardial infarction ("MI"), congestive heart failure ("CHF"), and other ischemic events affecting the heart, at early onset of patient chest pain. The invention further relates to diagnosis of the stage of the MI in a patient suffering from MI, and to prognosis of such a patient.

Abstract: A method of screening a cell for the onset of senescence or a senescent state therein comprises detecting a p21-E2F complex in the cell, an elevation in the complex as compared to a normal cell indicating the onset of senescence or a senescent state in the cell. Isolated complexes comprised of p21 and E2F are also disclosed. The complexes stably bind to DNA and are useful, among other things, for binding DNA.

Abstract: Adrenal autoantigen is isolated and characterised as a protein obtainable from the microsome fraction of the adrenal gland, having a molecular weight of about 55,000 and antigenic towards adrenal autoantibody. The protein is used in a method for detecting adrenal autoantibodies.

Abstract: The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.

Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.

Abstract: The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.

Abstract: Disclosed is a method of predicting the onset of fetal membrane rupture in a gestative female comprising the step of assaying a tissue or fluid sample of fetal membrane origin obtained from the female for the presence of pro-metalloproteinase-9 (pro-mmd-9). The presence of pro-mmd-9 in the sample is a positive indication of the onset of fetal membrane rupture. Also disclosed is a method of delaying the onset of female membrane rupture in a gestative female comprising the step of administering to the female an MMP-9 inhibitor in an amount effective to delay fetal membrane rupture. Further disclosed is a method of inducing labor in a gestative female comprising the administration of an MMP-9 activator or MMP-9 itself in an amount effective to induce fetal membrane rupture, and thus facilitate the onset of labor.

Abstract: The invention relates to an improved method for the manufacture of magnetically responsive particles, also called ferrofluids. The improved method involves a heat treatment step, which may occur at various times during the preparation of the materials, including during subdivision of the magnetic starting material, during the addion of a coating material, after formation of a magnetically responsive particle, or some combination thereof. The materials formed by such a process have numerous advantages over materials formed by other processes, including enhanced salt stability, increased coating uptake, and increased binding capacity. These ferrofluids have applications in a variety of preparative and diagnostic techniques, including immunoassay, cell separations, toxicity testing, food testing, environmental analysis, and MRI.

Abstract: The invention provides a method for the purification of a mammalian thymidine kinase 1. Also provided is a purified mammalian TK1, obtained from Raji cells, that is stable in the absence of stabilizing agents, has a molecular weight of approximately 100 kD and exhibits enzyme activity associated with the native 100 kD tetrameric species of TK1 but not the monomeric subunit. This purified TK1 was used to prepare a monoclonal antibody which inhibited TK1 enzyme activity. This anti-TK1 monoclonal antibody was used in methods for the diagnosis of cancer and for predicting the recurrence of cancer.

Abstract: A composition is provided which is a transducing polymer having from 1 to 20 crosslinks per polymer molecule and selected from the group consisting of amphoteric co- or ter-polymers of pI between 6.2 to 8.0 of acrylic acid, alkyl methacrylate, and N,N-dimethly-aminoethyl methacrylate, the amphoteric co- or ter-polymer immobilized on a surface. Also provided is a method for the preparation of an analyte-responsive polymer immobilized on a surface in which the steps are a. mixing a solution of a crosslinker and the claimed transducing polymer, b. applying the solution of step a to a surface, and c. then curing the polymer to a ratio of from 1 to 20 crosslinks per transducing polymer molecule. Acoustic and optical methods for detecting analtyes are also provided which use an analyte-responsive polymer.

Abstract: The present invention is drawn to an immunoassay capable of the rapid detection of a variety of test substances that may be present in a test sample. One feature of the invention is that extraction or isolation of the test substance occurs simultaneously with the formation of the primary antigen-test substance complex. The primary antigen-test substance complex is then captured in a solid phase format having a plurality of interstitial spaces which facilitate rapid and efficient detection. The immunoassay of the present invention works over a wide range of environmental conditions and is simple enough to be used in the absence of laboratory facilities.

Abstract: .beta.1,4-N-acetyl-galactosamine-transferase catalyzes the addition of N-acetyl-galactosamine in .beta.1,4-linkage to subterminal galactose substituted with an .alpha.2,3-linked N-acetyl-neuraminic acid residue.

Abstract: The present invention relates to a xylanase from the family Desulfurococcaceae, specifically to a xylanase from the genus Pyrodictium and more specifically to a xylanase from Pyrodictium abyssi and in particular to a xylanase from Pyrodictium abyssi, DSM 6158, which has (a) activity optimum in the pH range 5.5-6.5 at 100.degree. C. with xylan as a substrate and (b) activity optimum at the temperature range 105.degree.-115.degree. C., determined at pH 5.5 with xylan as a substrate. The present invention also relates to a process of bleaching lignocellulosic pulp with said xylanase.

Abstract: Disclosed is a method of diagnosing Alzheimer's disease in a patient by measuring the level of cathepsin D in the patient's cerebrospinal fluid.

Abstract: A method for the evaluation of the condition of a fetus by quantitative measurement of prostate specific antigen (PSA) is provided. In the method, a sample of amniotic fluid or maternal serum is obtained at a gestational week and the sample is assayed for the amount of PSA present. The amount of PSA in the sample is compared with the PSA mean for the given gestational week and evaluated for the risk of a phenotypic and/or genotypic disorder.

Abstract: The invention relates to the discovery that serum ferritin concentrations are elevated in patients at risk for the development of Acute Respiratory Distress Syndrome (ARDS) and who subsequently develop ARDS, as compared to at-risk patients who do not subsequently develop ARDS. Thus, the invention includes a method for determining ARDS development potential in an at-risk patient comprising the steps of determining the patient's serum concentration of ferritin and determining ARDS development potential from said serum concentration of ferritin.

Abstract: A method is described for performing an affinity assay comprising contacting a sample to be assayed for the presence of an analyte with a dry reagent containing the analyte (hapten, antigen, antibody, receptor, or complementary polynucleotide) bound to a reaction cascade initiator, an antibody or other binding pair partner reactive with said analyte, and magnetic particles, to form an assay mixture in a reaction chamber, incubating the assay mixture, applying an oscillating or moving static magnetic field to the assay mixture, activating the reaction cascade initiator to initiate a reaction cascade, monitoring the response of the magnetic particles to the oscillating or moving static magnetic field to provide a time varying signal, and determining the analyte concentration of the sample by analysis of the time varying signal, as well as a kit for performing the assay and a diagnostic system for performing the assay.

Abstract: Method of assay of enzymatic activity, comprising projecting excitation light to a sample containing an enzyme, a substrate which forms a product by action of the enzyme, and a reference substance which is insensitive to the action of the enzyme but emits fluorescence; obtaining a first measured value of fluorescence intensity of the sample at a first wavelength region which includes fluorescence emitted by the substrate or the product at least, obtaining a second measured value of fluorescence intensity at a second wavelength region which is different from the first wavelength region for the first measured value and includes fluorescence emitted by the reference substance; and assaying the enzymatic activity from the ratio of the first measured value to the second measured value and apparatus for performing the method. The method assures high accuracy and high sensitivity of measurement in enzyme labeled immunoassay and enzyme labeled DNA hybridization.

Abstract: A process for inducing cytochrome P-450 enzyme production in bacteria of the genus Streptomyces using inducers such as soybean flour, genistein or genistin is described. Uses for the cytochrome P-450 enzymes produced are also discussed as is a process for using genetically engineered Streptomyces to determine the mutagenicity of chemicals.

Abstract: In a process for the manufacture of C.sub.1 -C.sub.18 alkylglycoside ester of C.sub.4 -C.sub.24 fatty acids, the reactants are first formed into a stable micro-emulsion before they are contacted with an enzyme catalyst. The stable micro-emulsion is prepared, using a surface-active material, which is preferably the alkylglycoside ester formed.

Abstract: The precision of identification of analyte composition in a sample, where the possible analytes each provide a series of values for characteristic parameters; in particular where the parameters are generated by cross-reaction with specific binding reagents, is enhanced by applying pattern recognition techniques. Samples to be tested are evaluated with respect to each survey parameter to obtain a pattern of parameter values with respect to each analyte at a given concentration. In the case of the use of a panel of specific binding reagents, the samples to be tested are reacted with this panel and the affinities at various analyte concentrations are determined. This results in a databank of "SC profiles" for known concentrations of each analyte. This databank is stored in a computationally accessible form, which then can be matched against SC profiles obtained by testing unknown samples.

Abstract: Assays for identifying human patients at risk for developing insulin-dependent diabetes mellitus rely on detection of autoantibodies to a 38 kD autoantigen present in pancreatic .beta.-cells in patient sera. It has been found that autoantibodies to this particular autoantigen developed in patients well before clinical onset of the disease in a significant subpopulation of prediabetic patients. Useful assays will frequently combine detection of autoantibodies to the 38 kD autoantigen with detection of other known markers of IDDM, such as autoantibodies to a 64 kD autoantigen (glutamic acid decarboxylase).

Abstract: A method is provided for measuring an analyte in a sample comprising adding substantially transparent particles to a sample in solution or suspension, said particles having an affinity for said analyte; fractionating the particles from the solution or suspension to form a particle-rich fraction and a substantially particle-free fraction; optically reading the particle-rich fraction at a first and a second wavelength; optically reading the substantially particle-free fraction at at least the first wavelength; and correlating the readings through the particle-rich fraction and the substantially particle-free fraction of the sample, with similar measurements in a particle-containing "blank" to obtain a quantitative determination of the analyte originally present in the sample.

Abstract: An exo-enzyme having an ability to cut .beta.-(2.fwdarw.1) fructoside bond or a microorganism which produces the enzyme is allowed to act on a saccharide solution containing cyclic inulooligosaccharide in which fructose molecules are bonded through .beta.-(2.fwdarw.1) bond in a cyclic configuration, and other saccharides such as monosaccharide, disaccharide, linear oligosaccharide and inulin, and then the cyclic inulooligosaccharide is collected from an obtained saccharide solution. Thus cyclic inulooligosaccharide can be purified inexpensively at a high yield without using any solvent.

Abstract: Disclosed is a novel .alpha.-glycosyl derivative of a catecholamine or its salt, said .alpha.-glycosyl derivative being prepared by allowing a saccharide-transferring enzyme together with or without glucoamylase to act on a solution containing an .alpha.-glucosyl saccharide and one of catecholamines in order to form an .alpha.-glycosyl derivative of said catecholamines, and recovering the resultant .alpha.-glycosyl derivative. The .alpha.-glycosyl derivative overcomes conventional drawbacks of catecholamines, and does not substantially exhibit or have a reducing activity and undesirable toxicity, but has a relatively-high stability and exerts the inherent physiological activities of catecholamines in vivo. Thus, the .alpha.-glycosyl derivative is advantageously used as a variety of pharmaceuticals in the form of an injection, tablet, etc.

Abstract: The present invention relates to the field of cancer immunoassay. Specifically, a new immunoassay method for prostate specific antigen (PSA) is presented. Also presented is a complex which resembles a complex of PSA and .alpha.-antichymotrypsin (ACT) that can be used as a calibrator or control in an immunoassay for PSA. Further presented is a method for fractionating polyclonal antibodies, to PSA, into those which bind epitopes that are masked by the binding of PSA to ACT and those which do not bind such epitopes.

Abstract: A method of regio-and stereoselective hydrolysis to deprotect an acylated hydroxy group in acylated carbohydrates, which contributes to synthesis of complex oligosaccharides, is provided. The method utilizes catalytic antibodies as hydrolase.

Abstract: Glycosphingolipid compounds represented by the following formula ##STR1## wherein R is ##STR2## possess B cell mitogen activity and can be used as B cell activators.

Abstract: A non-radioactive method of detecting the enzymes beta galactosidase or beta glucosidase directly or for the detection of a ligand and antiligand complex is provided wherein beta galactosidase or the complex labelled with beta galactosidase or a tracer having beta galactosidase conjugated thereto is reacted with 5-bromo-4-chloro-3-indolyl-B-D-galactoside and a tetrazolium salt to produce a colored formazan or a color change indicative of the presence of beta galactosidase, or wherein beta glucosidase or the complex labelled with the beta glucosidase or a tracer having beta glucosidase conjugated thereto is reacted with 5-bromo-4-chloro-3-indolyl-B-D-glucoside and a tetrazolium salt to produce a colored formazan or a color change indicative of the presence of beta glucosidase. Optionally, the galactosidase-galactoside determination or the glucosidase-glucoside determination may further include catalyst phenazine methosulfate (PMS) as a reactant.

Abstract: A process suitable for use in the sequencing of an oligosaccharide compound includes a first analysis of a primary oligosaccharide compound's monosaccharide composition, selection of sequencing agents to apply to the oligosaccharide compound, applying a selected sequencing agent to the oligosaccharide compound, and analyzing a released monosaccharide to select a second sequencing agent. The sequencing agent may be, for example, an enzyme. The oligosaccharide compound may be, for example, an oligosaccharide, or a product of an oligosaccharide, or a species having an oligosaccharide portion.

Abstract: It was found that atopic allergens have enzymatic properties, in particular the properties to hydrolyze amide and/or ester linkages. These properties may be used for various purposes, e.g. for analysis of samples, standardization of pharmaceutical compositions and also for the preparation of the allergens in a pure form.

Abstract: Neoglycoconjugates and new intermediates for the synthesis thereof are synthesized by use of Endo-.beta.-N-acetylglucosaminidase from Arthrobacter protophormiae (Endo-A) in a medium containing an organic solvent.

Abstract: Bacterial strains are capable of the formation of rhamnolipids, which they generate in the culture solution. If bacteria of the type Pseudomonas aeruginosa are employed for the fermentation, these microorganisms synthesize rhamnolipids in a concentration of 70-120 g/l of culture solution. The L-rhamnose can be recovered directly from the culture solution by hydrolysis of the rhamnolipids, i.e. without a complicated separation of the cell material and without isolation of the rhamnolipids before hydrolysis.